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Abstract: Osteomyelitis is a devasting disease caused by the infection of bone tissue and is 
associated with significant morbidity and mortality. It is treated with antibiotic therapy and 
surgical debridement. A high dose of systemic antibiotics is often required due to poor bone 
penetration and this is often associated with unacceptable side-effects. To overcome this; local; 
implantable antibiotic carriers such as polymethyl methacrylate have been developed. However; 
this is a non-biodegradable material that requires a second surgery to be removed. As a result; 
attention has shifted to new antibiotic-eluting scaffolds which can be created with a range of 
unique properties. The purpose of this review is to assess the level of evidence that exists for these 
novel local treatments. Although this field is still developing; these strategies seem promising and 
provide hope for the future treatment of chronic osteomyelitis. 
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1. Osteomyelitis 
Osteomyelitis is an inflammatory bone disease caused by infection. It is most commonly 
associated with skin commensals such as the bacterium Staphylococcus aureus [1]. These organisms 
can be introduced by a variety of routes. The most common of these is trauma, with infection rates as 
high as 16% being reported in open long-bone fractures [2,3]. Other causes include joint arthroplasty 
and diabetic foot disease, both of which are becoming increasingly more prevalent as populations 
age [4–6]. Osteomyelitis can also result from the haematogenous spread of bacteria and this is 
especially important to consider in children. Fortunately, the incidence of bloodborne osteomyelitis 
has dramatically reduced following the introduction of systemic antibiotics [7]. 
Patients with osteomyelitis present with a variety of symptoms. Some of these are relatively 
non-specific, such as malaise, fatigue, chills, delayed healing and pyrexia [1]. Others tend to be more 
localised: pain at the site of infection, swelling and erythema [1]. Recognition of these features 
should prompt clinicians to obtain blood cultures, a full set of blood tests, inflammatory markers, 
plain x-ray films and a magnetic resonance imaging (MRI) scan [1,8]. Notably, the symptoms of 
osteomyelitis can either present themselves acutely, or chronically. The distinction between these 
subsets is pivotal to treatment. 
In acute osteomyelitis, patients are treated empirically with high-dose intravenous antibiotics 
[1]. Typically, a broad-spectrum agent is initiated and then refined by culture results [1]. The 
standard course of treatment lasts four to six weeks [1,9]. However, once there is dead bone, bone 
abscesses or biofilm formation, complete surgical debridement is also required [10]. This is usually 
the case in chronic osteomyelitis [10]. Details of the debridement surgery depend on the Cierny–
Mader classification and clinical context (Figure 1) [11]. This is a staging system for osteomyelitis 
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based on the anatomical boundaries of infection and the physiological status of the host. 
Intra-operative samples should always be taken for microbiology and histology assessment [10]. 
 
 
Figure 1. Simplified Cierny–Mader classification. Panel A: cross-sectional view of osteomyelitis in a 
long bone. Panel B: a longitudinal view with a window of bone removed. Stage 1 (medullary) 
osteomyelitis is confined to the medullary cavity. Stage 2 (superficial) involves the cortical bone and 
most often originates from direct inoculation or contiguous infection. Stage 3 (localised) involves 
both cortical and medullary bone. Stage 4 (diffuse) involves the entire thickness of the bone with a 
loss of stability. This figure was based on the original Cierny–Mader classification [11]. 
2. Local Treatments 
Because bone is an inflexible tissue, following bone loss such as in trauma and debridement 
surgery, any bony defect will remain and fill with haematoma [12]. This provides an ideal 
environment for bacteria to multiply and establish chronic infection and/or a biofilm. These bacteria 
go on to release osteolytic cytokines and osteonecrosis factors which evoke a powerful inflammatory 
response [13]. Over time, this can further damage the underlying bone and its blood supply. The 
result is a highly resilient biofilm in an area of increasingly poor antibiotic access. It has been 
reported that to treat these cases, a 10 to 100 times increase in antibiotic concentrations is required 
[14]. The use of high-dose systemic antibiotic treatment is expensive and associated with an 
increased risk of side effects [14,15]. It is therefore important to prevent chronic infection occurring. 
One way in which this can be done is by filling the bony defect(s) with a bone graft, material such as 
polymethyl methacrylate or a scaffold to prevent haematoma formation. In the US alone, the annual 
cost of treating bone defects has been estimated to be $5 billion [16]. 
2.1. Polymethyl Methacrylate 
The most popular local treatment is an antibiotic-eluting material called polymethyl 
methacrylate (PMMA) or ‘bone cement’ [17]. This has been referred to as the gold-standard of 
chronic osteomyelitis treatment [17,18]. Experimental studies have shown that PMMA can deliver in 
the order of 200 times the amount that systemic antibiotics are able to [19]. In animals, Evans and 
Nelson (1993) found that PMMA beads had a 100% success rate at preventing the recurrence of 
osteomyelitis [20]. However, randomised controlled trials in humans have failed to identify a 
difference in outcome between PMMA and systemic antibiotics [21–23]. In addition, the high 
temperatures generated during the preparation of PMMA can degrade its antibiotic content and 
induce thermal necrosis. This means certain antibiotics such as tetracyclines cannot be used [18]. 
Others have described a rare ‘bone cement implantation syndrome’ with PMMA use [24]. This is 
thought to be due to a leachable MMA monomer that causes local tissue toxicity and systemic effects 
such as hypoxia and confusion [24]. Perhaps the most concerning disadvantages of PMMA, is that 
the majority of the antibiotic loaded is not released and every patient requires a second operation for 
it to be removed [17]. This increases morbidity, hospital costs, recovery time and the risk of 
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perioperative complications such as infection. Attention has therefore shifted to alternative local 
treatments such as resorbable antibiotic scaffolds. 
2.2. Scaffolds 
A bone scaffold is a three-dimensional (3D) matrix that fills defective bone and facilitates repair. 
In the context of tissue engineering, many of these scaffolds are biodegradable and capable of 
osteoconduction, osteoinduction and osteogenesis [25]. These are defined as the abilities to guide 
reparative bone growth, encourage osteoblastic differentiation and contribute living bone cells 
respectively. In addition, they can deliver anti-inflammatory drugs and antibiotics [26]. This enables 
high concentrations to be delivered directly to an affected site without systemic side effects. It also 
overcomes any issues with drug bioavailability, compliance and allows for a sustained release 
pattern [26]. Antibiotic-eluting scaffolds have been classified as natural, synthetic or composite for 
the purpose of this article. 
3. Properties of an Antibiotic-Eluting Scaffold 
3.1. Biocompatability 
One of the most important properties of any bone graft is biocompatibility [27]. This helps to 
prevent a severe inflammatory response that may impair healing or cause rejection [27]. However, 
human leukocyte antigen (HLA) matching is infrequently performed for bone allografts [28,29]. This 
is in spite of growing evidence to suggest that allosensitisation occurs. Currently, the long-term 
effect of HLA sensitisation on bone graft survival is unknown. In comparison, autografts derived 
from the patient are inherently biocompatible but require a harvest surgery to be obtained. Synthetic 
and composite scaffolds represent an alternative therapy. These scaffolds can be designed and 
produced ex-vivo, to mimic native tissue and have as little immunogenicity as possible [30].  
3.2. Biodegradability 
The long-term presence of non-biodegradable scaffolds has been associated with impaired bone 
formation, difficult radiological assessment of bone healing, inflammation and prolonged drug 
release [25]. For example, the non-biodegradable material PMMA has been shown to elute low levels 
of antibiotic up to five years post-implantation [31]. Extended exposure to low-dose, sub-therapeutic 
levels of antibiotic is a major risk factor for bacterial resistance. In the aforementioned case, 
gentamicin-resistant staphylococci were recovered from the surface of the PMMA beads [30]. In 
another study that used gentamicin-eluting PMMA, 90% of the bacteria isolated were found to be 
resistant compared to 16% for plain cement [32]. It has also been suggested that chronic, unnecessary 
exposure to drugs such as gentamicin may cause nephrotoxicity, even at a low dose [33]. Those with 
renal impairment are especially at risk [33]. Moreover, when complete elution from a 
non-biodegradable scaffold is eventually achieved, the material acts as a foreign body and can 
become colonised, leading to recurrent infections [34]. In these cases, a second surgery is needed to 
remove the material. On the other hand, biodegradable scaffolds completely unload their antibiotic 
content over a defined time period and do not linger in the body. This avoids many of the 
disadvantages mentioned above and eliminates the need for retrieval surgery. Biodegradability is 
therefore a key property of a successful bone scaffold [26]. It is important that the rate of degradation 
is balanced with the rate of bone formation. 
3.3. Mechanical and Structural Properties 
Given that bone scaffolds are implanted in areas of dead space, they should have mechanical 
properties consistent with that anatomical site to prevent the risk of fracture [27]. However, scaffolds 
must also exhibit sufficient porosity to allow cellular penetration, angiogenesis and the transport of 
oxygen, nutrients and waste products [35,36]. In addition, a porous spatial arrangement enables 
drug release from deep inside the material. It has been shown that in vivo, that macroporous 
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antibiotic-loaded calcium phosphates out-perform microporous variants due to a higher antibiotic 
release rate (up to 13x more) [37]. This is not the case with PMMA which exhibits surface-level 
diffusion [38]. There is therefore a trade-off between mechanical strength and porosity. 
3.4. Bone Growth 
Other desirable properties of scaffolds include osteoconduction, osteoinduction and 
osteogenesis [25,39,40]. Osteoconduction is the ability to guide reparative bone growth. This is 
generally an intrinsic property and may be achieved by using a porous structure [41]. 
Osteoinduction on the other hand is the ability to encourage osteoblastic differentiation. This is an 
extrinsic process driven by the release of growth factors such as bone morphogenic proteins (BMPs) 
[41]. Osteogenesis, or the ability to contribute living cells, may be achieved by impregnating 
scaffolds with a variety of cell types [42]. 
3.5. Manufacturing Properties 
The ideal bone scaffold must also be cost-effective, easy-to-use and scalable. One way the 
production of scaffolds can be maximised, is through the use of three-dimensional printing. 
Three-dimensional printers are thought to decrease long-term purchase costs once the high set up 
and maintenance expenses have been recompensed. Antibiotic-eluting scaffolds can be produced 
using this method if a thermostable drug such as tobramycin is used [43]. Many of these materials 
have been shown to be efficacious in both in vitro and in vivo models of osteomyelitis [43,44]. In the 
latter study, 3D-printed resorbable calcium phosphate scaffolds containing sitafloxacin and rifampin 
outperformed gentamicin-laden PMMA when bacterial colonization outcomes and bone growth 
were assessed [44]. Another benefit of 3D-printing is that it allows for the fabrication of 
patient-specific designs which completely fill the bone void. An alternative approach to achieve this 
is to manufacture injectable scaffolds that harden in vivo [45].  
4. The Choice of Antibiotic 
A successful local antibiotic must have good tissue penetration and predictable 
pharmacokinetics [46]. The choice of drug is also guided by the clinical context. For example, in cases 
of osteomyelitis that are culture positive for methicillin-resistant Staphylococcus aureus (MRSA), a 
vancomycin-eluting scaffold should be used [6,47]. If the organism is unknown or the treatment is 
prophylactic, one may instead opt for a broader-spectrum drug such as tobramycin which is 
effective against both gram-positive and gram-negative bacteria [48]. One must also consider 
patient-specific factors when choosing an antibiotic. These include allergy, co-morbidities, 
susceptibility to side-effects and the dose required. In some reports, authors have instead used a 
combination-based approach. This involves impregnating a single scaffold with a mixture of 
synergistic antibiotics, such as gentamicin, vancomycin and clindamycin [45,49]. The use of 
combination therapy is thought to increase the likelihood of eradication and minimise the risk of 
antibiotic resistance [50]. It is therefore likely to be used more frequently as this field develops. 
5. Natural Scaffolds 
Given the importance of biocompatibility and biodegradability, natural scaffolds such as 
collagen, hyaluronic acid, cellulose and chitosan may seem like sensible biomaterials to use in 
osteomyelitis [26]. Natural polymers are biologically active and typically promote excellent cell 
adhesion and growth [27]. However, they are also immunologically active and carry the risk of 
rejection [26]. In addition, they generally have poor mechanical properties which limit their use in 
load-bearing orthopaedic applications [26,27].  
5.1. Collagen 
Collagen is the most abundant protein in mammalian tissue and forms a key component of the 
extracellular matrix [51]. It is also the most widely explored natural biomaterial [34]. A recent 
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systematic review of 413 patients treated with antibiotic-loaded collagen sponges (fleeces) reported 
an overall success rate of 91% [52]. However, the authors also identified a moderate to high risk of 
bias in these studies [52]. Moreover, the pharmacokinetic profiles of these materials showed an 
average local antibiotic concentration that was above the bacterial minimum inhibitory 
concentration (MIC), for only five days [52]. This rapid antibiotic release rate of collagens has long 
been documented. In a study by Sorensen et al. (1990) for example, the authors found that their 
collagen sponge eluted 95% of its gentamicin in the first day in vitro [53]. It is also important to note 
that like other natural scaffolds, collagen is a weak biomaterial. To improve its mechanical strength 
collagen can be crosslinked, or more effectively, it can be combined with synthetic materials to form 
composite scaffolds [54,55]. 
5.2. Chitosan 
Polysaccharides are a further group of natural biomaterials and include chitosan, a derivative of 
chitin which is found in arthropod skeletons. Chitosan shares many of the advantages and 
disadvantages as collagen-based scaffolds. For example, it is also mechanically weak and has a 
compressive strength one to two orders lower than cancellous bone [56]. Chitosan has hydrophilic 
elements and a positive charge which enables it to interact with negatively charged polymers, 
macromolecules and certain polyanions [26]. This means that it lacks structural stability in aqueous 
environments—a critical requirement of any bone scaffold [26,56]. On the other hand, these 
properties enable chitosan to form a ‘hydrogel’ that can be exploited for drug-delivery and 
nanoencapsulation purposes [26,56]. Some authors even attribute the cationic nature of chitosan 
with an intrinsic antimicrobial ability [57]. Chitosan is therefore an unsuitable bone substitute when 
used alone, but can be very useful when blended with other materials to improve its mechanical and 
structural properties when hydrated. For this reason, chitosan-based composites are being 
increasingly used in bone tissue engineering [58].  
6. Synthetic Scaffolds 
Synthetic scaffolds are a large, rapidly expanding category of biomaterials. These includes 
calcium phosphates and synthetic polymers. 
6.1. Polymers 
The most commonly used synthetic polymers are polyurethane (PUR) and saturated aliphatic 
polyesters such as poly(lactic acid) (PLA), poly(glycolic acid) (PGA), poly(lactic-co-glycolic acid) 
(PLGA) and poly(carprolactones) (PCL) [26,17,59]. Like natural scaffolds, these products are 
generally biocompatible and biodegradable [59]. However, synthetic polymers have longer release 
rates and can be produced under more controlled manufacturing methods [35]. This means that they 
have predictable physicomechanical properties and can be engineered, for example, by adjusting the 
molecular weight, to yield specific desired characteristics [35]. The versality of these scaffolds is their 
largest advantage [26]. One disadvantage though, is that compared to native bone, synthetic 
polymers have relatively poor mechanical properties [59]. This makes them unsuitable for use in 
high load-bearing areas [26]. Moreover, they degrade by hydrolysis which produces carbon dioxide. 
This has been reported to lower the surrounding pH, resulting in tissue necrosis [60,61]. In scaffolds 
that rapidly dissolve, this change in pH may even be large enough to reduce the functional efficacy 
of the local antibiotic [17]. For these reasons, antibiotic-eluting synthetic polymers remain the focus 
of in vitro and in vivo experiments [45,61,62]. 
An example of the utility of these materials is provided by Li et al. (2010) [62]. This group used 
biodegradable PUR scaffolds impregnated with free-base vancomycin, to treat 40 rats with 
post-traumatic osteomyelitis [62]. Using this method, the authors found the bacterial load at four 
weeks (measured in colony forming units) was significantly lower than that of negative controls [62]. 
The effectiveness of this resorbable scaffold was comparable to PMMA which is the current standard 
of care [62]. In another study by McLaren et al. (2014), a biodegradable PLGA scaffold was used to 
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deliver gentamicin and clindamycin to 30 sheep with osteomyelitis [45]. These animals were 
sacrificed at two- and six-weeks post-implantation to look for evidence of infection. No bacteria 
were isolated from animals treated with antibiotic-eluting scaffolds, but Staphylococcus aureus was 
successfully isolated from control groups [45]. The authors also showed that at 13 weeks the scaffold 
material had fully degraded [45]. Any area of the defect that was not filled with new bone contained 
cartilaginous tissue that would be expected to eventually turn into mineralised bone [45]. Synthetic 
polymers are therefore promising biomaterials. They are contained in many recent composites that 
have been used in clinical trials as discussed below. 
6.2. Calcium phosphates 
Calcium-based bone substitutes are a particularly large group of materials used in bone tissue 
engineering [35]. These include calcium sulfates, tricalcium phosphate (TCP), hydroxyapatite (HA) 
and biphasic calcium phosphates (TCP + HA). Unlike natural scaffolds and synthetic polymers, the 
chemical and operation properties of calcium products are similar to the mineral phase of bone [63]. 
The high mechanical stiffness (Young’s modulus), hardness, brittleness and low elasticity make 
calcium substitutes appropriate for bone regeneration [63]. Compared with human bone, the 
compressive strength of calcium phosphates is generally much higher, though they have a lower 
tensile strength, fracture toughness and increased fragility [63,64]. Calcium-based scaffolds are also 
biocompatible, osteoconductive and bioactive, meaning that they are capable of forming a biological 
interface with host tissue [65]. This can help to prevent implant dislocation. However, it has been 
postulated that the dissolution of calcium sulfate, like other synthetics, leads to an acidic 
microenvironment which may cause inflammation [66]. There is also evidence to suggest that some 
products which are marketed as being resorbable, may still persist over several years in some 
patients [67]. This is not ideal as the defect should be replaced by new, stronger bone in all cases. 
The potential of antibiotic-eluting, biodegradable, calcium-based scaffolds in chronic 
osteomyelitis has been long recognised [68]. As a result, there is a wealth of literature in this area. 
Importantly, this has led to numerous clinical trials with positive results (Table 1). It has also 
inspired companies to mass-produce calcium-based products. Many of these, such as OSTEOSET®-T 
(resorbable alpha hemihydrate calcium sulfate + tobramycin) have received approval by the Food 
and Drug Administration (FDA) in the United States. However, a recent systematic review of 484 
patients has highlighted that many of these papers have a significant risk of bias [69]. The authors 
therefore warn that while these results may seem promising, they are currently inconclusive [69]. Of 
those listed in Table 1, only McKee et al. (2010) conducted a prospective randomised trial and even 
then, no blinding was put in place [70]. There is therefore a need for more recent, larger-scale 
randomised-control trials in this area [69]. Care should also be taken when extrapolating the results 
of studies based on osteomyelitis, to other contexts. It has recently been shown that 
antibiotic-impregnated calcium sulfate beads do not improve outcomes in periprosthetic joint 
infections, for example [71]. 
Table 1. Clinical studies focusing on antibiotic-eluting, resorbable, calcium-based scaffolds for 
chronic osteomyelitis. 
Authors 
Number of 
Patients  
Material 
Systemic 
Antibiotics 
Used 
Mean 
Follow-up 
(yrs) 
Eradication 
Rate 
Other Outcomes 
McKee et al. 
2002 [68] 
25 
OSTEOSET®-T (calcium 
sulfate + tobramycin) 
Yes 2.3 92% 
12% fracture, 32% wound leak, 36% had 
autologous bone grafting. 
McKee et al. 
2010 [70] 
15 
OSTEOSET®-T (calcium 
sulfate + tobramycin) 
Yes 3.2 
86% (same 
result as 
PMMA) 
14% fracture, 21% wound leak, 33% 
underwent further surgical procedures. 
Fleiter et al. 
2014 [72] 
20 
HERAFILL® G (calcium 
sulfate + calcium carbonate 
+ gentamicin) 
No 0.5 80% 
No adverse outcomes reported, sufficient 
gentamicin elution rates measured. 
Humm et al. 
2014 [73] 
21 
OSTEOSET®-T (calcium 
sulfate + tobramycin) 
Yes 1.3 95% 
33.3% wound discharge, 100% union rate, 
24% delayed wound-healing or pin-site 
infections. 
Ferguson et 
al. 2014 [67] 
195 
OSTEOSET ®-T (calcium 
sulfate + tobramycin) 
Yes 3.7 91% 
4.7% fracture (at a mean of 1.9 years), 15.4% 
wound leak, radiographic bone filling absent 
in 36.6%, partial in 59% and complete in 8%. 
McNally et 100 CERAMENT® G (calcium Yes 1.6 96% 3% fracture, 6% wound leak. 
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al. 2016 [74] sulfate + hydroxyapatite + 
gentamicin) 
7. Composite Scaffolds 
Composite scaffolds are the current focus of bone tissue engineering [35]. They combine 
different materials with unique properties in an attempt to overcome the deficiencies of the 
individual constituents. For example, bio-ceramic composites are made of calcium-based scaffolds 
and synthetic polymers. This allows the composite to have the typical mechanical strength, 
bioactivity and osteoconductive properties associated with calcium substitutes, but also overcome 
their fragility issues [26]. Other common preparations include calcium-based or synthetic polymer 
scaffolds, with natural polymers such as collagen or chitosan. Recently, it has been shown in vitro 
that beta-TCP-collagen composites have a significantly higher loading capacity and a steadier 
release rate of gentamicin and vancomycin compared to TCP and HA granules [75]. Theoretically, 
composites can incorporate any number of the above materials. They have even been made with 
other antimicrobials such as bioactive glass and various metal ions [76,77]. The relative proportions 
of each constituent material can drastically change features such as the drug release profile, bacterial 
inhibition zone and ultimately, the outcome in vivo [77,78]. Considering the above, there is therefore 
a near-infinite number of possible composites. This is therefore a very promising field of bone tissue 
engineering. However, as a relatively new advancement, there are no clinical studies on 
antibiotic-eluting composites for osteomyelitis. Recent experimental studies are highlighted in Table 
2. It must be noted that the transfer of in vitro results to in vivo studies is difficult, even in animals. 
Table 2. Experimental studies focusing on antibiotic-eluting, composite scaffolds for chronic 
osteomyelitis. 
Authors 
Study 
Type 
Materials Main Finding[s] 
Cheng et al. 
2017 [76] 
In vitro Bioglass + PLGA + vancomycin 
Supported the fewest viable bacteria compared to controls after 24h of S. 
aureus culture. Effect was maintained even after 6 cycles of exposure. 
Wang et al. 
2017 [79] 
 
In vivo 
(rabbits) 
Silica microspheres + nano-HA 
+ polyurethane + levofloxacin 
(lev) 
Increased bone formation compared to controls and lev-PMMA at 6- and 
12-weeks. After this time, the scaffold began to degrade. 
Zhou et al. 
2018 [78] 
In vivo 
(rabbits) 
Gelatin + β-TCP + vancomycin 
At 8 weeks, the radiological and histopathological severities were significantly 
better than controls (7.3x and 3.66x respectively). 
Kamboj et 
al. 2019 [80] 
In vitro 
Silicon–calcium silicate + 
polycaprolactone + vancomycin 
(3D-printed) 
Observed a two-step, controlled antibiotic release profile: ~50% during the 
first 40h, then sustained release of 20% over the next 6 days. 
Kuang et al. 
2019 [81] 
In vitro 
Silica microspheres + nano-HA 
+ polyurethane + levofloxacin 
Observed increased osteogenic differentiation of bone marrow stem cells at 14 
days, a lower number of bacterial colony units at 12 days, decreased apoptosis 
of osteoblast precursors and decreased microbial adhesion compared to 
controls. 
Zhang et al. 
2019 [77] 
In vivo 
(rats) 
Silk + nanosilver + gentamicin 
Lower colony count at 3 weeks compared to controls. Four of the six cases in 
this group inhibited bacterial growth completely. 
8. Other Antimicrobial Materials 
In addition to antibiotic-loaded bone scaffolds, there are also other antimicrobial biomaterials 
including bioactive glass [82]. This is a biodegradable, osteoconductive, osteoinductive and 
osteogenic material that kills bacteria by leaching ionic dissolution products from its surface [83,84]. 
This changes the local osmotic pressure and pH such that it is hostile to microbial growth [84]. It has 
also been shown to be angiogenic in vitro [85]. However, disadvantages of bioactive glass include 
brittleness and a low fracture toughness [86]. Bioactive glass S53P4 has been the focus of a large 
multinational study of 116 patients across six countries with chronic osteomyelitis [87]. This research 
reported a cure rate of 90% at a median follow-up length of 31 months [87]. There is some evidence 
that the antibacterial effect of bioactive glass can be further improved by doping them with metal 
ions such as zinc, strontium or silver [87]. These materials in themselves have antimicrobial 
properties [88]. In a recent study be Mestres et al. (2010), for example, magnesium-containing 
cements were shown to have intrinsic antimicrobial activity and were sufficient alone, to 
significantly improve the health state of animals [37]. Other antimicrobials include enzyme-loaded 
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scaffolds and polymeric nanoparticles [89,90]. The latter is especially notable, as no bacterial 
resistance was observed towards these materials in vitro after 20 serial passages (1300 bacterial 
generations) [90]. On the other hand, resistance occurred after only a few passages for clinically 
relevant antibiotics [90]. The usefulness of nanoparticles in bone tissue engineering has been 
summarised by several authors [91,92]. 
9. Conclusion 
Antibiotic-eluting scaffolds present many advantages over other local methods for the 
treatment of osteomyelitis. This is a dynamic field that has seen many exciting advances. Natural, 
synthetic and composite bone substitutes have all been developed, some of which have moved into 
clinical trials. Perhaps the most promising of these are the biodegradable, antibiotic-eluting 
composite scaffolds. These can be designed to incorporate the best features of all available 
biomaterials and can be 3D-printed, therefore allowing scalability and/or patient-specificity [93]. 
Composites have come at a time when the field of bone tissue engineering is moving away from the 
concept of an ‘ideal’ bone substitute, towards applications that depend on the clinical context [94–
96]. There is still a need for large-scale randomised control trials in this area before definitive 
conclusions can be reached. It also remains to be fully explored how antibiotic-eluting composite 
scaffolds can be made to interact with other pathways involved in bone repair, namely growth factor 
signaling and cell-based therapies. 
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